Innoviva (INVA) Current Deferred Revenue (2010 - 2026)
Innoviva posted quarterly Current Deferred Revenue of $3.7 million for Q1 2026, up 266.97% year-on-year from $1.0 million in Q1 2025, and down 13.89% on a QoQ basis from $4.3 million in Q4 2025.
Innoviva (INVA) has 13 years of Current Deferred Revenue data on file, last reported at $3.7 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue rose 266.97% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.7 million (up 266.97% YoY), and the FY2025 full-year result was $4.3 million, up 279.22% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $3.7 million, down from $4.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $13.6 million in Q3 2025 and bottomed at $717000.0 in Q3 2024.
- The 5-year median for Current Deferred Revenue is $2.1 million (2022), against an average of $2.8 million.
- The widest annual swing landed in 2024, when Current Deferred Revenue plunged 73.72%; it then soared 1792.75% in 2025.
- A 5-year view of Current Deferred Revenue shows it stood at $2.1 million in 2022, then plunged by 39.02% to $1.3 million in 2023, then fell by 11.82% to $1.1 million in 2024, then soared by 279.22% to $4.3 million in 2025, then fell by 13.89% to $3.7 million in 2026.
- The last three Current Deferred Revenue figures came in at $3.7 million (Q1 2026), $4.3 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.68 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 13.57 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 717,000.00 |
| Jun 30, 2024 | 855,000.00 |
| Mar 31, 2024 | 987,000.00 |
| Dec 31, 2023 | 1.28 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 2.09 Mn |
| Dec 31, 2022 | 2.09 Mn |
| Sep 30, 2022 | 2.85 Mn |
| Sep 30, 2017 | 885,000.00 |
| Jun 30, 2017 | 885,000.00 |
| Mar 31, 2017 | 885,000.00 |
| Dec 31, 2016 | 885,000.00 |
| Sep 30, 2016 | 885,000.00 |
| Jun 30, 2016 | 885,000.00 |
| Mar 31, 2016 | 885,000.00 |
| Dec 31, 2015 | 885,000.00 |
| Sep 30, 2015 | 885,000.00 |
| Jun 30, 2015 | 885,000.00 |
| Mar 31, 2015 | 885,000.00 |
| Dec 31, 2014 | 1.08 Mn |
| Sep 30, 2014 | 1.08 Mn |
| Jun 30, 2014 | 1.08 Mn |
| Mar 31, 2014 | 8.81 Mn |
| Dec 31, 2013 | 9.29 Mn |
| Sep 30, 2013 | 9.60 Mn |
| Jun 30, 2013 | 8.97 Mn |
| Mar 31, 2013 | 9.88 Mn |
| Dec 31, 2012 | 4.59 Mn |
| Sep 30, 2012 | 4.95 Mn |
| Jun 30, 2012 | 5.77 Mn |
| Mar 31, 2012 | 5.77 Mn |
| Dec 31, 2011 | 18.70 Mn |
| Sep 30, 2011 | 20.89 Mn |
| Jun 30, 2011 | 20.55 Mn |
| Dec 31, 2010 | 21.92 Mn |